Properties of the NO-ASA family of NO-donating NSAIDs (NO-NSAIDs), notably NCX 4016
(mNO-ASA) and NCX 4040 (pNO-ASA), reported in more than one hundred publications …

Nitric oxide-donating nonsteroidal anti-inflammatory drugs (NO-NSAIDs) consist of a
conventional NSAID to which an NO-releasing moiety is attached covalently, often via a …

NO (nitric oxide) biology has provided the impetus for the development of anticancer agents
based on their ability to release NO. NO-NSAIDs (NO-donating non-steroidal anti …

The chemoprevention of colon cancer, the second leading cause of cancer-related deaths in
the United States, has been pursued actively during the last two decades. Methodological …

Three potential applications of NO-donating NSAIDs in human cancer include their use: as
chemopreventive agents; against already developed cancers (chemotherapy); and for the …

Nonsteroidal anti-inflammatory drugs (NSAIDs) have shown promise in colorectal cancer
(CRC), but they are compromised by gastrotoxicity. NO-NSAIDs are hybrid nitrates …

NO-NSAIDs are promising anticancer drugs, comprising an NSAID, an NO-releasing moiety,
and a spacer linking them. Although the effect of NO-NSAIDs on a wide variety of signaling …

Nitric-oxide-donating nonsteroidal anti-inflammatory drugs (NO–NSAIDs), which consist of
an NSAID with an NO-donating moiety covalently attached to it, promise to contribute …

Cellular defense mechanisms that respond to damage from oxidative and electrophilic
stress, such as from quinones, represent a target for chemopreventive agents. Drugs …

The novel nitric oxide-donating nonsteroidal antiinflammatory drugs (NO-NSAIDs),
consisting of a traditional NSAID to which a NO releasing moiety is covalently attached, may …